Autolus Therapeutics
Developing next-generation programmed T-cell therapies for cancer.
Autolus is a clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer.
Using proprietary T-cell programming technologies, the company is engineering precisely targeted and controlled therapies designed to recognise and eliminate cancer cells. The drug is known as obecabtagene autoleucel (obe-cel, marketed as AUCATZYL), which has approvals in the US, EU and UK.
Autolus was founded on research led by Dr Martin Pule at the UCL Cancer Institute.
The Autolus journey so far:
- 2014: Autolus is founded
- 2018: IPO on NASDAQ for $160 million
- 2024:
- Phase 1 lupus trial initiated
- FDA approval of obe-cel for adult ALL
- 2025:
- Phase 1 clinical trial for multiple sclerosis initiated
- EMA approval of obe-cel in the EU for adult ALL
- MHRA and later NICE approval of obe-cel in England for adult ALL
- 2026:
- Early results reported from lupus trial
- Aucatzyl used for the first time in an NHS patient with ALL
Updates from Autolus
Events & programmes
Autolus founder discusses the long journey from research to impact
Academic-turned-founder Dr. Martin Pule spoke about the realities and rewards taking cancer therapies to market at I-O Converse.
Spinout & portfolio news
Early promise reported in severe lupus for Autolus’ CAR T therapy
A CAR T-cell therapy developed by a UCL Ventures' spinout has shown early results for people with severe, treatment-resistant lupus.
Opinion & insights
What is CAR T? The technology behind Autolus’ cancer hope
CAR T harnesses the power of a patient’s immune system to combat their cancer.
Team
Dr Martin Pule
Founder and Chief Scientific Officer
Dr Pule's is an Associate Professor in haematology. His research focuses on many aspects of genetic engineering of T-cells for cancer treatment.
Dr. Rick Fagan
Director of BioPharm
Dr Fagan is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada. This was followed by a postdoctorate at the Imperial Cancer Research Fund, London, and then the
National Institute for Medical Research.
Richard left to join AstraZeneca as a team leader in the Department of Target Discovery, then worked for SanofiAventis as a senior team leader. In 2001 he left SanofiAventis and joined Impharmatica as Associate Director Target Discovery and worked very closely with the business development team.
In 2006 he joined UCL Ventures as Assistant Director BioPharm, becoming Director in 2007.